Bristol Myers Squibb Files Proxy Materials
Ticker: CELG-RI · Form: DEFA14A · Filed: Apr 15, 2025 · CIK: 14272
| Field | Detail |
|---|---|
| Company | Bristol Myers Squibb Co (CELG-RI) |
| Form Type | DEFA14A |
| Filed Date | Apr 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-governance
Related Tickers: BMY
TL;DR
BMS filed proxy docs, no fee. Standard corporate stuff.
AI Summary
Bristol Myers Squibb Company filed a Definitive Additional Materials proxy statement on April 15, 2025. This filing is related to the company's proxy materials and does not involve a fee. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing is a standard procedural document for Bristol Myers Squibb, indicating the company is proceeding with its corporate governance and shareholder communication processes.
Risk Assessment
Risk Level: low — This is a routine SEC filing for proxy materials and does not contain new financial information or strategic decisions that would inherently increase risk.
Key Players & Entities
- Bristol Myers Squibb Company (company) — Registrant
- 0001140361-25-013981 (filing_id) — Accession Number
- 20250415 (date) — Filing Date
- DEFA14A (form_type) — SEC Filing Type
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is Bristol Myers Squibb Company.
When was this filing made?
The filing was made on April 15, 2025.
Is there a fee associated with this filing?
No, the filing indicates 'No fee required'.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 15, 2025 regarding BRISTOL MYERS SQUIBB CO (CELG-RI).